| Company Name: |
Foshan Heshuo Pharm technology Co., ltd
|
| Tel: |
15363639686 |
| Email: |
heshuoyiyao@hotmail.com |
| Products Intro: |
Product Name:Valopicitabine dihydrochloride
CAS:640725-71-9
Purity:95%+ Package:50mg;100mg;500mg
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Valopicitabine dihydrochloride
CAS:640725-71-9
Purity:95.00% Package:2mg;25mg;50mg
|
Valopicitabine dihydrochloride manufacturers
|
| | Valopicitabine dihydrochloride Basic information |
| | Valopicitabine dihydrochloride Chemical Properties |
| Melting point | 210 °C | | storage temp. | Store at -20°C, protect from light, stored under nitrogen | | form | Solid | | color | White to off-white |
| | Valopicitabine dihydrochloride Usage And Synthesis |
| Uses | Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination[1][2]. | | in vivo | Valopicitabine (NM283) (100 mg/kg; oral administration; Sprague-Dawley Rats) dihydrochloride shows the Cmax, AUC, t1/2, and tmax were 3.624 μg/mL, 8.95 μg h/mL, 0.64 hours and 1 hour, respectively[2]. | | References | [1] Liu-Young G, et al. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS. 2008;22(6):449-457. DOI:10.1089/apc.2007.0199
[2] Pierra C, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J Med Chem. 2006;49(22):6614-6620. DOI:10.1021/jm0603623 |
| | Valopicitabine dihydrochloride Preparation Products And Raw materials |
|